Targeting spleen tyrosine kinase-bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis

Jin Shuen Chen, Li Chien Chang, Shyh Jer Huang, Chao Wen Cheng

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The importance of B-cell activation and immune complex-mediated Fc-receptor activation in the pathogenesis of immunologically mediated glomerulonephritis has long been recognized. The two nonreceptor tyrosine kinases, spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (Btk), are primarily expressed by hematopoietic cells, and participate in B-cell-receptor- and Fc-receptor-mediated activation. Pharmacological inhibitors of Syk or Btk are undergoing preclinical development and clinical trials for several immune diseases; and Syk inhibitors have been shown to reduce disease activity in rheumatoid arthritis patients. However, the clinical therapeutic efficacies of these inhibitors in glomerulonephritis have not been evaluated. Herein, we review recent studies of Syk and Btk inhibitors in several experimental primary and secondary glomerulonephritis models. These inhibitors suppressed development of glomerular injury, and also ameliorated established kidney disease. Thus, targeting Syk and Btk signaling pathways is a potential therapeutic strategy for glomerulonephritis, and further evaluation is recommended.

Original languageEnglish
Article number814869
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Glomerulonephritis
Protein-Tyrosine Kinases
Fc Receptors
Chemical activation
Cells
B-Lymphocytes
Antigen-Antibody Complex
Immune System Diseases
Kidney Diseases
Rheumatoid Arthritis
Agammaglobulinaemia tyrosine kinase
Syk Kinase
Clinical Trials
Pharmacology
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Targeting spleen tyrosine kinase-bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis. / Chen, Jin Shuen; Chang, Li Chien; Huang, Shyh Jer; Cheng, Chao Wen.

In: BioMed Research International, Vol. 2014, 814869, 2014.

Research output: Contribution to journalArticle

@article{99478866e82543cd99fd8a034d447e47,
title = "Targeting spleen tyrosine kinase-bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis",
abstract = "The importance of B-cell activation and immune complex-mediated Fc-receptor activation in the pathogenesis of immunologically mediated glomerulonephritis has long been recognized. The two nonreceptor tyrosine kinases, spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (Btk), are primarily expressed by hematopoietic cells, and participate in B-cell-receptor- and Fc-receptor-mediated activation. Pharmacological inhibitors of Syk or Btk are undergoing preclinical development and clinical trials for several immune diseases; and Syk inhibitors have been shown to reduce disease activity in rheumatoid arthritis patients. However, the clinical therapeutic efficacies of these inhibitors in glomerulonephritis have not been evaluated. Herein, we review recent studies of Syk and Btk inhibitors in several experimental primary and secondary glomerulonephritis models. These inhibitors suppressed development of glomerular injury, and also ameliorated established kidney disease. Thus, targeting Syk and Btk signaling pathways is a potential therapeutic strategy for glomerulonephritis, and further evaluation is recommended.",
author = "Chen, {Jin Shuen} and Chang, {Li Chien} and Huang, {Shyh Jer} and Cheng, {Chao Wen}",
year = "2014",
doi = "10.1155/2014/814869",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Targeting spleen tyrosine kinase-bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis

AU - Chen, Jin Shuen

AU - Chang, Li Chien

AU - Huang, Shyh Jer

AU - Cheng, Chao Wen

PY - 2014

Y1 - 2014

N2 - The importance of B-cell activation and immune complex-mediated Fc-receptor activation in the pathogenesis of immunologically mediated glomerulonephritis has long been recognized. The two nonreceptor tyrosine kinases, spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (Btk), are primarily expressed by hematopoietic cells, and participate in B-cell-receptor- and Fc-receptor-mediated activation. Pharmacological inhibitors of Syk or Btk are undergoing preclinical development and clinical trials for several immune diseases; and Syk inhibitors have been shown to reduce disease activity in rheumatoid arthritis patients. However, the clinical therapeutic efficacies of these inhibitors in glomerulonephritis have not been evaluated. Herein, we review recent studies of Syk and Btk inhibitors in several experimental primary and secondary glomerulonephritis models. These inhibitors suppressed development of glomerular injury, and also ameliorated established kidney disease. Thus, targeting Syk and Btk signaling pathways is a potential therapeutic strategy for glomerulonephritis, and further evaluation is recommended.

AB - The importance of B-cell activation and immune complex-mediated Fc-receptor activation in the pathogenesis of immunologically mediated glomerulonephritis has long been recognized. The two nonreceptor tyrosine kinases, spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (Btk), are primarily expressed by hematopoietic cells, and participate in B-cell-receptor- and Fc-receptor-mediated activation. Pharmacological inhibitors of Syk or Btk are undergoing preclinical development and clinical trials for several immune diseases; and Syk inhibitors have been shown to reduce disease activity in rheumatoid arthritis patients. However, the clinical therapeutic efficacies of these inhibitors in glomerulonephritis have not been evaluated. Herein, we review recent studies of Syk and Btk inhibitors in several experimental primary and secondary glomerulonephritis models. These inhibitors suppressed development of glomerular injury, and also ameliorated established kidney disease. Thus, targeting Syk and Btk signaling pathways is a potential therapeutic strategy for glomerulonephritis, and further evaluation is recommended.

UR - http://www.scopus.com/inward/record.url?scp=84899546812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899546812&partnerID=8YFLogxK

U2 - 10.1155/2014/814869

DO - 10.1155/2014/814869

M3 - Article

C2 - 24795896

AN - SCOPUS:84899546812

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 814869

ER -